ADC Therapeutics (ADCT) News Today $2.39 -0.26 (-9.81%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comBrokerages Set ADC Therapeutics SA (NYSE:ADCT) Target Price at $8.25November 11, 2024 | americanbankingnews.comADC Therapeutics Highlights Q3 Advances and Strategic FocusNovember 10, 2024 | markets.businessinsider.comADC Therapeutics SA (ADCT) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comStephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight RecommendationNovember 9, 2024 | msn.comADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating tNovember 8, 2024 | marketbeat.comStephens Initiates Coverage on ADC Therapeutics (NYSE:ADCT)Stephens began coverage on shares of ADC Therapeutics in a research report on Friday. They set an "overweight" rating and a $6.00 target price for the company.November 8, 2024 | marketbeat.comADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdateNovember 7, 2024 | prnewswire.comADC Therapeutics's Earnings: A PreviewNovember 6, 2024 | benzinga.comADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual MeetingNovember 5, 2024 | prnewswire.comADC Therapeutics to Present at November Investor ConferencesNovember 4, 2024 | prnewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanNovember 1, 2024 | prnewswire.comADC Therapeutics (ADCT) to Announce Earnings on ThursdayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024October 31, 2024 | prnewswire.comInstitutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)October 28, 2024 | finance.yahoo.comADC Therapeutics S.A.October 16, 2024 | wsj.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Increases By 13.4%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 3,560,000 shares, an increase of 13.4% from the September 15th total of 3,140,000 shares. Based on an average daily trading volume, of 394,400 shares, the days-to-cover ratio is currently 9.0 days.October 15, 2024 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanOctober 1, 2024 | globenewswire.comAffinity Asset Advisors LLC Makes New Investment in ADC Therapeutics SA (NYSE:ADCT)Affinity Asset Advisors LLC bought a new position in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 474,744 shares of the company's stock, valSeptember 25, 2024 | marketbeat.com205,221 Shares in ADC Therapeutics SA (NYSE:ADCT) Bought by Bank of New York Mellon CorpBank of New York Mellon Corp acquired a new stake in ADC Therapeutics SA (NYSE:ADCT - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 205,221 shares of the company's stock, valued at approximatelySeptember 24, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Trading 0.5% Higher ADC Therapeutics (NYSE:ADCT) Stock Price Up 0.5%September 12, 2024 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanSeptember 3, 2024 | globenewswire.comADC Therapeutics to Present at Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short InterestADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 3,000,000 shares, a decrease of 6.0% from the July 15th total of 3,190,000 shares. Based on an average daily volume of 756,400 shares, the days-to-cover ratio is currently 4.0 days.August 19, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) to Post FY2024 Earnings of ($2.04) Per Share, Cantor Fitzgerald ForecastsADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for ADC Therapeutics in a research report issued to clients and investors on Wednesday, August 7th. Cantor Fitzgerald analyst E. Schmidt now anticipatAugust 9, 2024 | marketbeat.comRBC Capital Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)August 8, 2024 | markets.businessinsider.comADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSADC Therapeutics (NYSE:ADCT - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. The firm had revenue of $17.41 million for the quarter, compared to the consensus estimate of $19.06 million. During the same period in the prior year, the company earned ($0.58) EPS.August 7, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Wednesday.August 7, 2024 | marketbeat.comBuy Rating Upheld for ADC Therapeutics SA Amidst Strong Financials and Promising Oncology PipelineAugust 7, 2024 | markets.businessinsider.comADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 6, 2024 | finanznachrichten.deADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 6, 2024 | globenewswire.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanAugust 1, 2024 | globenewswire.comADC Therapeutics (ADCT) Set to Announce Earnings on TuesdayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Tuesday, August 6, Zacks reports.July 31, 2024 | marketbeat.comADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024July 30, 2024 | globenewswire.com7 Growth Stocks to Buy for Under $5 for Massive GainsJuly 11, 2024 | investorplace.comMyricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentJuly 8, 2024 | globenewswire.comRedmile Group, Llc Buys 400,000 Shares of ADC Therapeutics SA (NYSE:ADCT) StockJuly 4, 2024 | insidertrades.comRedmile Group, Llc Acquires 400,000 Shares of ADC Therapeutics SA (NYSE:ADCT) StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) major shareholder Redmile Group, Llc bought 400,000 shares of ADC Therapeutics stock in a transaction dated Monday, July 1st. The stock was purchased at an average price of $2.81 per share, with a total value of $1,124,000.00. Following the purchase, the insider now directly owns 12,995,040 shares in the company, valued at approximately $36,516,062.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.July 3, 2024 | marketbeat.comADC Therapeutics Set to Join Russell 2000® and Russell 3000® IndexesJune 27, 2024 | globenewswire.comADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by AnalystsADC Therapeutics SA (NYSE:ADCT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the compaJune 24, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Director Sells $20,215.55 in StockJune 19, 2024 | insidertrades.comStocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a BudgetJune 13, 2024 | investorplace.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanJune 3, 2024 | globenewswire.comADC Therapeutics SA (NYSE:ADCT) Sees Significant Growth in Short InterestADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 1,000,000 shares, an increase of 16.6% from the April 30th total of 857,600 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 566,800 shares, the days-to-cover ratio is currently 1.8 days.June 2, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by BrokeragesADC Therapeutics SA (NYSE:ADCT - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recomMay 30, 2024 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns Overweight Rating from Analysts at Cantor FitzgeraldCantor Fitzgerald initiated coverage on ADC Therapeutics in a report on Thursday. They issued an "overweight" rating for the company.May 30, 2024 | marketbeat.comADC Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | globenewswire.comADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 15, 2024 | globenewswire.comADC Therapeutics First Quarter 2024 Earnings: In Line With ExpectationsMay 10, 2024 | finance.yahoo.comAmeet Mallik Sells 29,731 Shares of ADC Therapeutics SA (NYSE:ADCT) StockMay 10, 2024 | insidertrades.com Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now ADCT Media Mentions By Week ADCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.280.56▲Average Medical News Sentiment ADCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼42▲ADCT Articles Average Week Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NKTR News MRSN News ITOS News CCCC News CTMX News ALEC News VERV News PCRX News AVBP News ETNB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADCT Stock Alerts